Breast Tumor Cytogenetic Markers

  • Marilyn L. Slovak
Part of the Contemporary Biomedicine book series (CB, volume 13)


Breast cancer is the most frequent neoplasm in women from Western countries (1), with a cumulative lifetime breast cancer risk of about 1 in 10 (2). Most cases are sporadic, but familial clustering is observed in ~20% of breast tumors and at least 5–10% of cases appear to be a result of the inheritance of an autosomal dominant gene (3–5). The exact number and distribution of predisposing genes is currently unknown. The underlying etiology of breast cancer is poorly understood, and only recently have several genetic-based mechanisms emerged (6,7). This lack of essential genetic information is a major limitation to the development of clinical applications in breast cancer.


Breast Cancer Breast Tumor Breast Carcinoma Primary Breast Cancer Human Breast Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. Canadian Cancer J Clin 45:8–30, 1995.Google Scholar
  2. 2.
    King M, Rowell S, Love SM: Inherited breast and ovarian cancer: What are the risks? What are the choices? JAMA 269:1975–1980, 1993.PubMedGoogle Scholar
  3. 3.
    Lynch HT, Albano WA, Danes BS, Layton MA, Kimberling WJ, Lynch JF, Cheng SC, Costello KA, Mulchahy GM, Wagner CA, Tindall SL: Genetic predisposition to breast cancer. Cancer 53:612–622, 1984.PubMedGoogle Scholar
  4. 4.
    Wolman SR, Dawson PJ: Genetic events in breast cancer and their clinical correlates. Crit Rev Oncogene 2:277–291, 1991.Google Scholar
  5. 5.
    Rowell S, Newman B, Boyd J, King MC: Inherited predisposition to breast and ovarian cancer. Am J Hum Genet 55:861–865, 1994.PubMedGoogle Scholar
  6. 6.
    Devilee P, Cornelisse CJ: Somatic genetic changes in human breast cancer. Biochem Biophys Acta 1198:113–130, 1994.PubMedGoogle Scholar
  7. 7.
    Devilee P, Schuuring E, van de Vijver MJ, Cornelisse CJ: Recent developments in the molecular genetic understanding of breast cancer. Oncogene 5:247–270, 1994.Google Scholar
  8. 8.
    Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa APM, Lidereau R: Somatic mutations and human breast cancer. Cancer 69:1582–1588, 1992.Google Scholar
  9. 9.
    Mitelman F: Catalog of Chromosome Aberrations in Cancer. Johansson B, Mertens F (eds.), New York: Wiley-Liss, 1994.Google Scholar
  10. 10.
    Weber-Matthiesen K, Winkemann M, Muller-Hermelink A, Schegelberger B, Grote W: Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem 40:171–175, 1992.PubMedGoogle Scholar
  11. 11.
    Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Pinkel D, Gray J, Waldman FM: Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res 52: 3474–3477, 1992.PubMedGoogle Scholar
  12. 12.
    Cajulis RS, Frias-Hidvegi D: Detection of numerical chromosomal abnormalities in malignant cells in fine needle aspirates by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes. Acta Cytologica 37:391–396, 1993.PubMedGoogle Scholar
  13. 13.
    Abati A, Sanford JS, Fetsch P, Marincola FM, Wolman SR: Fluorescence in situ hybridization (FISH): a user’s guide to optimal preparation of cytologic specimens. Diagn Cytol 13:485–492, 1995.Google Scholar
  14. 14.
    Dhingra K, Sahin A, Supak J, Kim SY, Hortobagyi G, Hittelman WN: Chromosome in situ hybridization on formalin-fixed mammary tissue using non-isotopic, non-fluorescent probes: technical considerations and biological implications. Breast Cancer Res Treat 23:201–210, 1992.PubMedGoogle Scholar
  15. 15.
    Kallioniemi O, Kallioniemi A, Kurisu W, Thor A, Chen L, Smith HS, Waldman FM, Pinkel D, Gray JW: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321–5325, 1992.PubMedGoogle Scholar
  16. 16.
    Wolman SR, Sanford JS, Flom K, Feiner H, Abati A, Bedrossian C: Genetic probes in cytology: principles and practice. Diagn Cytol 13:429–435, 1995.Google Scholar
  17. 17.
    Wolman SR, Smith HS, Stampfer M, Hackett AJ: Growth of diploid cells from breast cancers. Cancer Genet Cytogenet 16:49–64, 1985.PubMedGoogle Scholar
  18. 18.
    Zhang R, Wiley J, Howard SP, Meisner LF, Gould MN: Rare clonal karyotype variants in primary cultures of human breast carcinoma cells. Cancer Res 49:444–149, 1989.PubMedGoogle Scholar
  19. 19.
    Geleick D, Muller H, Matter A, Torhorst J, Regenass U: Cytogenetics of breast cancer. Cancer Genet Cytogenet 46:217–219, 1990.PubMedGoogle Scholar
  20. 20.
    Bullerdiek J, Leuschner E, Taquia E, Bonk U, Bartnitzke S: Trisomy 8 as a recurrent clonal abnormality in breast cancer? Cancer Genet Cytogenet 65:64–67, 1993.PubMedGoogle Scholar
  21. 21.
    Pandis N, Heim S, Bardi G, Idvall I, Mandahl N, Mitelman F: Chromosome analysis of 20 breast carcinomas: cytogenetic multiclonality and karyotypic-pathologic correlations. Genes Chromosom Cancer 6:51–57, 1993.PubMedGoogle Scholar
  22. 22.
    Smith HS, Liotta LA, Hancock MC, Wolman SR, Hackett AJ: Invasiveness and ploidy of human mammary carcinomas in short-term culture. Proc Natl Acad Sei USA 82:1805–1809, 1985.Google Scholar
  23. 23.
    Trent J: Cytogenetic and molecular biologic alterations in human breast cancer: a review. Breast Cancer Res Treat 5:221–229, 1985.PubMedGoogle Scholar
  24. 24.
    Thompson F, Emerson J, Dalton W, Yang JM, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharyya A, Trent J: Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease. Genes Chromosom Cancer 7:185–193, 1993.PubMedGoogle Scholar
  25. 25.
    Atkin NB, Baker MC: Are human cancers ever diploid—or often trisomic? Conflicting evidence from direct preparations and cultures. Cytogenet Cell Genet 53:58–60, 1990.PubMedGoogle Scholar
  26. 26.
    Slovak ML, Ho J, Simpson JF: Cytogenetic studies of 46 human breast carcinomas. Proc Am Assoc Cancer Res 33:40, 1992.Google Scholar
  27. 27.
    Dupont WD, Page DL, Pari FF, Vnencak-Jones CL, Plummer WD, Rados MS, Schuyler PA: Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10–15, 1994.PubMedGoogle Scholar
  28. 28.
    Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151, 1985.PubMedGoogle Scholar
  29. 29.
    Dupont WD, Pari FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258–1265, 1993.PubMedGoogle Scholar
  30. 30.
    Levi F, Randimbison L, Van-Cong T, La Vecchia C: Incidence of breast cancer in women with fibroadenoma. Int J Cancer 57:681–683, 1994.PubMedGoogle Scholar
  31. 31.
    McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D: Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer 69:1408–1414, 1992.PubMedGoogle Scholar
  32. 32.
    Dietrich CY, Pandis N, Teixeira MR, Bardi G, Gerdes A, Andersen JA, Heim S: Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer 60:49–53, 1995.PubMedGoogle Scholar
  33. 33.
    Ozisik YY, Meloni AM, Stephenson CF, Peier A, Moore GE, Sandberg AA: Chromosome abnormalities in breast fibroadenomas. Cancer Genet Cytogenet 77:125–128, 1994.PubMedGoogle Scholar
  34. 34.
    Calabrese G, Di Virgilio C, Cianchett E, Guanciali Franchi P, Stuppia L, Parruti G, Bianchi PG, Palka G: Chromosome abnormalities in breast fibroadenomas. Genes Chromosom Cancer 3:202–204, 1991.PubMedGoogle Scholar
  35. 35.
    Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245, 1992.PubMedGoogle Scholar
  36. 36.
    Micale MA, Visscher DW, Gulino SE, Wolman SR: Chromosomal aneu-ploidy in proliferative breast disease. Hum Pathol 25:29–35, 1994.PubMedGoogle Scholar
  37. 37.
    Pandis N, Heim S, Bardi G, Idvall I, Mandahl N, Mitelman F: Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. Genes Chromosom Cancer 5:235–238, 1992.PubMedGoogle Scholar
  38. 38.
    Pandis N, Jin Y, Gorunova L, Petersson C, Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N, Mitelman F, Heim S: Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosom Cancer 12:173–185, 1995.PubMedGoogle Scholar
  39. 39.
    Dutrillaux B, Gerbault-Seureau M, Zafrani B: Characterization of chromosomal anomalies in human breast cancer: a comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet 49:203–217, 1990.PubMedGoogle Scholar
  40. 40.
    Pandis N, Teixeira MR, Gerdes A, Limon J, Bardi G, Andersen JA, Idvall I, Mandahl N, Mitelman F, Heim S: Chromosome abnormalities in bilateral breast carcinomas. Cancer 76:250–258, 1995.PubMedGoogle Scholar
  41. 41.
    Johansson B, Heim S, Mandahl N, Mertens F, Mitelman F: Trisomy 7 in nonneoplastic cells. Genes Chromosom Cancer 6:199–205, 1993.PubMedGoogle Scholar
  42. 42.
    Dal Cin P, Aly MS, Delabie J, Ceuppens JL, van Gool S, van Damme B, Baert L, van Poppel H, van den Berghe H: Trisomy 7 and trisomy 10 characterize subpopulations of tumor-infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. Proc Natl Acad Sci USA 89:9744–9748, 1992.Google Scholar
  43. 43.
    Rohen C, Meyer-Bolte K, Bonk U, Ebel T, Staats B, Leuschner E, Gohla G, Caselitz J, Bartnitzke S, Bullerdiek J: Trisomy 8 and 18 as frequent clonal and single-cell aberrations in 185 primary breast carcinomas. Cancer Genet Cytogenet 80:33–39, 1995.PubMedGoogle Scholar
  44. 44.
    Pandis N, Bardi G, Jin Y, Dietrich C, Johansson B, Andersen J, Mandahl N, Mitelman F, Heim S: Unbalanced t(1;16) as the sole karyotypic abnormality in a breast carcinoma and its lymph node metastasis. Cancer Genet Cytogenet 75:158–159, 1994.PubMedGoogle Scholar
  45. 45.
    Kreipe H, Feist H, Fischer L, Feigner J, Heidorn K, Mettler L, Parwaresch R: Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956–1961, 1993.PubMedGoogle Scholar
  46. 46.
    Pertschuk LP, Feldman JG, Kim DS, Nayeri K, Eisenberg KB, Carter AC, Thelmo WT, Rhong ZT, Benn P, Grossman A: Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Cancer 71:162–171, 1993.PubMedGoogle Scholar
  47. 47.
    Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P, Birnbaum D: FGFR1 and PLAT genes and DNA amplifcation at 8pl2 in breast and ovarian cancers. Genes Chromosom Cancer 7:219–226, 1993.PubMedGoogle Scholar
  48. 48.
    Bullerdiek J, Bonk U, Staats B, Leuschner E, Gohla G, Ebel T, Bartnitzke S: Trisomy 18 as the first chromosome abnormality in a medullary breast cancer. Cancer Genet Cytogenet 73:75–81, 1994.PubMedGoogle Scholar
  49. 49.
    Haldar S. Negrini M, Monne M, Sabbioni S. Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095–2097, 1994.PubMedGoogle Scholar
  50. 50.
    Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM, Carter DC: Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer 68:64–68, 1993.PubMedGoogle Scholar
  51. 51.
    Hainsworth PJ, Raphael KL, Stillwell RG, Bennett RC, Garson OM: Cytogenetic features of twenty-six primary breast cancers. Cancer Genet Cytogenet 52:205–218, 1991.Google Scholar
  52. 52.
    Pandis N, Bardi G, Heim S: Interrelationship between methodological choices and conceptual models in solid tumor cytogenetics. Cancer Genet Cytogenet 76:76–84, 1994.Google Scholar
  53. 53.
    Pandis N, Heim S, Bardi G, Limon J, Mandahl N, Mitelman F: Improved technique for short-term culture and cytogenetic analysis of human breast cancer. Genes Chromosom Cancer 5:14–20, 1992.PubMedGoogle Scholar
  54. 54.
    Pandis N, Jin Y, Limon J, Bardi G, Idvall I, Mandahl N, Mitelman F, Heim S: Interstitial deletion of the short arm of chromosome 3 as a primary chromosome abnormality in carcinomas of the breast. Genes Chromosom Cancer 6:151–155, 1993.PubMedGoogle Scholar
  55. 55.
    Steinarsdottir M, Petursdottir I, Snorradottir S, Eyfjord JE, Ogmundsdottir HM: Cytogenetic studies of breast carcinomas: different karyotypic profiles detected by direct harvesting of short-term culture. Genes Chromosom Cancer 13:239–248, 1995.PubMedGoogle Scholar
  56. 56.
    Mitchell ELD, Santibanez-Koref MF: 1p13 is the most frequently involved band in structural chromosomal rearrangements in human breast cancer. Genes Chromosom Cancer 2:278–289, 1990.PubMedGoogle Scholar
  57. 57.
    Mugneret F, Sidaner I, Favre B, Manone L, Maynadie M, Caillot D, Solary E: der(16) t(1; 16)(q 10;p 10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt’s type translocations. Leukemia 9:277–281, 1995.PubMedGoogle Scholar
  58. 58.
    Mugneret F, Dastugue N, Favre B, Sidaner I, Salles B: der(16)t(l;16)(ql 1; q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenetic and fluorescence in situ hybridization studies. Br J Haematol 90:119–124, 1995.PubMedGoogle Scholar
  59. 59.
    Douglass EC, Rowe ST, Valentine M, Parham D, Meyer WH, Thompson E: A scond nonrandom translocation, der(16)t(1; 16)(q21;q 13), in Ewing sarcoma and peripheral neuroectodermal tumor. Cytogenet Cell Genet 53:87–90, 1990.PubMedGoogle Scholar
  60. 60.
    Almeida A, Kokalj-Vokac N, Lefrancois D, Viegas-Pequignot E, Jeanpierre M, Dutrillaux B, Malfoy B: Hypomethylation of classical satellite DNA and chromosome instability in lymphoblastoid cell lines. Hum Genet 91:538–546, 1993.PubMedGoogle Scholar
  61. 61.
    Hainsworth PJ, Raphael KL, Stillwell RG, Bennett RC, Garson OM: Rearrangement of chromosome 1p in breast cancer correlates with poor prognostic features. Br J Cancer 66:131–135, 1992.PubMedGoogle Scholar
  62. 62.
    Devilee P, van Vliet M, Bardoel A, Kievitis T, Kuipers-Dijkshoorn N, Pearson PL, Cornelisse CJ: Frequent somatic imbalance of parental chromosomes 1 in human primary breast carcinoma. Cancer Res 51:1020–1025, 1991.PubMedGoogle Scholar
  63. 63.
    Larsson C, Bystrom C, Skoog L, Rotstein S, Nordenskjold M: Genomic alterations in human breast carcinomas. Genes Chromosom Cancer 2: 191–197, 1990.PubMedGoogle Scholar
  64. 64.
    Bieche I, Champeme M, Matifas F, Cropp CS, Callahan R, Lidereau R: Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53:1990–1994, 1993.PubMedGoogle Scholar
  65. 65.
    Genuardi M, Tsihira H, Anderson DE, Saunders GF: Distal deletion of chromosome 1p in ductal carcinoma of the breast. Am J Hum Genet 45: 73–82, 1989.PubMedGoogle Scholar
  66. 66.
    Bieche I, Champeme M, Merlo G, Larsen C, Callahan R, Lidereau R: Loss of heterozygosity of the L-myc oncogene in human breast tumors. Hum Genet 85:101–105, 1990.PubMedGoogle Scholar
  67. 67.
    Borg A, Zhang Q, Olsson H, Wenngren E: Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosom Cancer 5:311–320, 1992.PubMedGoogle Scholar
  68. 68.
    Bunnell B, Heath LS, Adams DE, Lahti JM, Kidd VJ: Elevated expression of a p58 protein kinase leads to changes in the CHO cell cycle. Proc Natl Acad Sci USA 87:7467–7471, 1987.Google Scholar
  69. 69.
    Bunnell B, Adams DE, Kidd VJ: Transient expression of a p58 protein kinase cDNA enhances mammalian glycosytransferase activity. Biochem Biophys Res Commun 171:196–203, 1990.PubMedGoogle Scholar
  70. 70.
    Eipers PG, Barnoski BL, Han J, Carroll AJ, Kidd VJ: Localization of the expressed human p58 protein kinase chromosomal gene to chromosome lp36 and a highly related sequence to chromosome 15. Genomics 11:621–629,1991.PubMedGoogle Scholar
  71. 71.
    Bieche I, Champeme M, Lidereau R: A tumor suppressor gene on chromosome lp32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res 54:4274–4276, 1994.PubMedGoogle Scholar
  72. 72.
    Trent J, Yang J, Emerson J, Dalton W, McGee D, Massey K, Thompson F, Villar H: Clonal chromosome abnormalities in human breast carcinomas II. Thirty-four cases with metastatic disease. Genes Chromosom Cancer 7:194–203,1993.PubMedGoogle Scholar
  73. 73.
    Bieche I, Champeme M, Lidereau R: Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1:123–127, 1995.PubMedGoogle Scholar
  74. 74.
    Chen L, Matsumura K, Deng G, Kurisu W, Ljung B, Lerman MI, Waldman FM, Smith HS: Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res 54:3021–3024, 1994.PubMedGoogle Scholar
  75. 75.
    Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y: Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 51:5794–5799, 1991.PubMedGoogle Scholar
  76. 76.
    Deng G, Chen L, Schott DR, Thor A, Bhargava V, Ljung B, Chew K, Smith HS: Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499–505, 1994.PubMedGoogle Scholar
  77. 77.
    Devilee P, van Vliet M, van Sloun P, Dijkshoorn NK, Hermans J, Pearson PL, Cornelisse CJ: Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene 6:1705–1711, 1991.PubMedGoogle Scholar
  78. 78.
    Orphanos V, McGrown G, Hey Y, Boyle JM, Santibanez-Koref M: Proximal 6q, a region showing allele loss in primary breast cancer. Br J Cancer 71:290–293, 1995.PubMedGoogle Scholar
  79. 79.
    Magdelenat H, Gerbault-Seureau M, Dutrillaux B: Relationship between loss of estrogen and progesterone receptor expression and of 6q and 11q chromosome arms in breast cancer. Int J Cancer 57:63–66, 1994.PubMedGoogle Scholar
  80. 80.
    Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG: Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Br J Cancer 71:448–450, 1995.PubMedGoogle Scholar
  81. 81.
    Bieche I, Champeme M, Matifas F, Hacene K, Callahan R, Lidereau R: Loss of heterozygosity on chromosome 7q and agressive primary breast cancer. Lancet 339:139–143, 1992.PubMedGoogle Scholar
  82. 82.
    Larsson C, Bystrom C, Skoog L, Rotstein S, Nordenskjold M: Genomic alterations in human breast carcinomas. Genes Chromosom Cancer 2: 191–197, 1990.PubMedGoogle Scholar
  83. 83.
    Zenklusen JC, Bieche I, Lidereau R, Conti CJ: (C-A)n microsatellite repeat D7S522 in the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91:12,155–12,158, 1994.Google Scholar
  84. 84.
    Champeme M, Bieche I, Beuzelin M, Lidereau R: Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosom Cancer 12:304–306, 1995.PubMedGoogle Scholar
  85. 85.
    Borresen A, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, Cornelisse CJ, Hovig E, Devilee P: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom Cancer 14:71–75, 1995.PubMedGoogle Scholar
  86. 86.
    Yaremko ML, Recant WM, Westbrook CA: Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosom Cancer 13:186–191, 1995.PubMedGoogle Scholar
  87. 87.
    Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, Donis-Keller H: Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q 16q, 17p, and 17q. Cancer Res 55:3399–3405, 1995.PubMedGoogle Scholar
  88. 88.
    Ferti-Passantonopoulou A, Panani AD, Raptis S: Preferential involvement of 11q23–24 and 11 p 15 in breast cancer. Cancer Genet Cytogenet 51: 183–188, 1991.PubMedGoogle Scholar
  89. 89.
    Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM: Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res 54:6270–6274, 1994.PubMedGoogle Scholar
  90. 90.
    Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK, Croce CM: Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 1 lq23.3. Cancer Res 55:3003–3007, 1995.PubMedGoogle Scholar
  91. 91.
    Theillet C, Lidereau R, Escot C, Hutzell P, Brunet M, Gest J, Schlom J, Callahan R: Loss of a c-Hras-1 allele and agressive human primary breast carcinomas. Cancer Res 46:4776–4781, 1986.PubMedGoogle Scholar
  92. 92.
    Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC: Incidence of activating ras oncogene mutations associated with primary metastatic human breast cancer. Cancer Res 49:357–360, 1989.PubMedGoogle Scholar
  93. 93.
    Winqvist R, Mannermaa A, Alavaikko M, Blanco G. Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W: Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res 53:4486–4488, 1993.PubMedGoogle Scholar
  94. 94.
    Mackay J, Elder PA, Steel CM, Forrest APM, Evans HJ: Allele loss on short arm of chromosome 17 in breast cancers. Lancet ii: 1384–1385, 1988.Google Scholar
  95. 95.
    Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmert-Buck MR: Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 55:467–471, 1995.PubMedGoogle Scholar
  96. 96.
    Schuuring E, Verhoeven E, vanTinteren H, Peterse JL, Nunnink B, Thunnissen FBJM, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Michalides RJAM: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52:5229–5234, 1992.PubMedGoogle Scholar
  97. 97.
    Gaffey MJ, Frierson HF, Williams ME: Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. Modern Pathol 6:654–659, 1993.Google Scholar
  98. 98.
    Tsuda HS, Hirohashi Y, Shimosato T, Hirota S, Tsugane H, Yamamoto N, Miyajima K, Toyoshima T, Yamamoto J, Yokota T, Yoshida H, Sakamoto H, Terada M, Suigmura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB2/ear-1. Cancer Res 49:3104–3108, 1989.PubMedGoogle Scholar
  99. 99.
    Champeme M, Bieche I, Lizard S, Lidereau R: 1 lql3 amplification in local recurrence of human primary breast cancer. Genes Chromosom Cancer 54 12:128–133,1995.Google Scholar
  100. 100.
    Borg A, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Olsson H, Killander D, McGurie WL: Association of int-2/hst-1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 63:136–142, 1991.PubMedGoogle Scholar
  101. 101.
    Brookes S, Lammie GA, Schuuring E, de Boer C, Michalides R, Dickson C, Peters G: Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG island telomeric of FGF3, including the expressed gene EMS1. Genes Chromsom Cancer 6:222–231, 1993.Google Scholar
  102. 102.
    Hampton GM, Mannermaa A, Winquist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans G A: Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 54:4586–4589, 1994.PubMedGoogle Scholar
  103. 103.
    Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, Goedde HW: Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet 90:635–640, 1993.PubMedGoogle Scholar
  104. 104.
    Tomlinson IPM, Stickland JE, Lee ASG, Bromley L, Evans MF, Morton J, O’D McGee J: Loss of heterozygosity on chromosome 1 1q in breast cancer. J Clin Pathol 48:424–428, 1995.PubMedGoogle Scholar
  105. 105.
    Winqvist R, Hampton GM, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H. Taskinen PJ, Evans GA, Wright FA, Newsham I, Cavenee WK: Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55: 2660–2664, 1995.PubMedGoogle Scholar
  106. 106.
    Lindblom A, Sandelin K, Iselius I, Dumanski J, White I, Nordenskjold M, Larsson C: Predisposition for breast cancer in carriers of constitutional translocation 11q;22q. Am J Hum Genet 54:871–876, 1994.PubMedGoogle Scholar
  107. 107.
    Cornelisse CJ, Kuipers-Dijkshoorn N, van Vliet M, Hermans J, Devilee P: Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 50:544–548, 1992.PubMedGoogle Scholar
  108. 108.
    Cleton-Jansen A, Moerland EW, Kuipers-Dijkshoorn JJ, Callen DF, Sutherland GR, Hansen B, Devilee P, Cornelisse CJ: At least two different regions are involved in allelic imbalanced on chromosome arm 16q in breast cancer. Genes Chromosom Cancer 9:101–107, 1994.PubMedGoogle Scholar
  109. 109.
    Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S: Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res 54:513–517, 1994.PubMedGoogle Scholar
  110. 110.
    Lindblom A, Rotstein S, Skoog L, Nordenskjold M, Larsson C: Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res 53:3707–3711, 1993.PubMedGoogle Scholar
  111. 111.
    Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y, Emi M: Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer 74:2281–2286, 1994.PubMedGoogle Scholar
  112. 112.
    Doggett NA, Callen DF: Report of the third international workshop on human chromosome 16 mapping 1994. Cytogenet Cell Genet 68: 166–177, 1995.Google Scholar
  113. 113.
    Silletti S, Yao J, Sanford J, Mohamed AN, Otto T, Wolman SR, Raz A: Autocrine motility factor receptor in human bladder cancer: gene expression, loss of cell-contact regulation, and chromosomal mapping. Int J Oncol 3:801–807, 1993.PubMedGoogle Scholar
  114. 114.
    Rosenberg C, Andersen TI, Nesland JM, Lier ME, Brogger A, Borresen A: Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA technigues. Cancer Genet Cytogenet 75:1–5, 1994.PubMedGoogle Scholar
  115. 115.
    Merlo GR, Venesio T, Bernardi A, Cropp CS, Diella F, Cappa APM, Callahan R, Liscia DS: Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet Cytogenet 76:106–111, 1994.PubMedGoogle Scholar
  116. 116.
    Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, Hoyheim B, Steel CM: Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 336:761–763, 1990.PubMedGoogle Scholar
  117. 117.
    Cornells RS, van Vliet M, Vos CBJ, Cleton-Jansen A, van de Vijver MJ, Peterse JL, Khan PM, Borresen A, Cornelisse CJ, Devilee P: Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200–4206, 1994.Google Scholar
  118. 118.
    Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, Wallace M, Wells SA, Donis-Keller HR: Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 53:2947–2950, 1993.PubMedGoogle Scholar
  119. 119.
    Kirchweger R, Zeillinger R, Schneeberger C, Speiser P, Louason G, Theillet C: Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. Int J Cancer 56:193–199, 1994.PubMedGoogle Scholar
  120. 120.
    Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J: p53 mutations in breast cancer. Cancer Res 52:5291–5298, 1992.PubMedGoogle Scholar
  121. 121.
    Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M: p53 mutations and histological type of invasive breast carcinoma. Cancer Res 53:4665–4669, 1993.PubMedGoogle Scholar
  122. 122.
    Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL: Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68:540–548, 1993.PubMedGoogle Scholar
  123. 123.
    Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, Witzig TE, Krook JE, Wieand HS, Kovach JS: p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 86:1871–1873,1994.PubMedGoogle Scholar
  124. 124.
    Davidoff AM, Kerns BM, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51:2605–2610, 1991.PubMedGoogle Scholar
  125. 125.
    Cheickh MB, Rouanet P, Louason G, Jeanteur P, Theillet C: An attempt to define sets of cooperating genetic alterations in human breast cancer. Int J Cancer 51:542–547, 1992.PubMedGoogle Scholar
  126. 126.
    Cornells RS, Devilee P, van Vliet, M, Kuipers-Dijkshoorn N. Kersenmaeker A, Bardoel A, Khan PM, Cornelisse CJ: Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions. Oncogene 8:781–785, 1993.Google Scholar
  127. 127.
    Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y: Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53:3382–3385, 1993.PubMedGoogle Scholar
  128. 128.
    Cropp CS, Champeme M, Lidereau R, Callahan R: Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res 53:5617–5619, 1993.PubMedGoogle Scholar
  129. 129.
    Cropp CS, Nevanlinna HA, Pyrhonen S, Stenman U, Salmikangas P, Albertsen H, White R, Callahan R: Evidence for involvement of BRCA1 in sporadic breast carcinomas. Cancer Res 54:2548–2551, 1994.PubMedGoogle Scholar
  130. 130.
    Futreal PA, Soderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, Wiseman RW: Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 52:2624–2627, 1992.PubMedGoogle Scholar
  131. 131.
    Nagai MA, Yamamoto L, Salaorni S, Pacheco MM, Brentani MM, Barbosa EM, Brentani RR, Mazoyer S, Smith SA, Ponder BAJ, Mulligan LM: Detailed deletion mapping of chromosome segment 17q 12–21 in sporadic breast tumours. Genes Chromosom Cancer 11:58–62, 1994.PubMedGoogle Scholar
  132. 132.
    Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wisemen R: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120–122, 1994.PubMedGoogle Scholar
  133. 133.
    Meravjer SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS: Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 9:439–443, 1995.Google Scholar
  134. 134.
    Aberle H, Bierkeamp C, Torchard D, Serova O, Wagner T, Natt E, Wirsching J, Heidkamper C, Montagna M, Lynch HT, Lenoir GM, Scherer G, Feunteun J, Kemler R: The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc Natl Acad Sci USA 92:6384–6388, 1995.PubMedGoogle Scholar
  135. 135.
    Slamon DJ, Gogolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707–712, 1989.PubMedGoogle Scholar
  136. 136.
    Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Paul Kitchen for the South Australian Breast Cancer Study Group: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936–1942,1993.PubMedGoogle Scholar
  137. 137.
    Lonn U, Lonn S, Nilsson B, Stenkvist B: Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 75:2681–2687, 1995.PubMedGoogle Scholar
  138. 138.
    Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50:6701–6707, 1990.PubMedGoogle Scholar
  139. 139.
    Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, Anamthawat-Jonsson K: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646–651, 1995.PubMedGoogle Scholar
  140. 140.
    Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543–546, 1992.PubMedGoogle Scholar
  141. 141.
    Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948, 1992.PubMedGoogle Scholar
  142. 142.
    Saint-Ruf C, Gerbault-Seureau M, Viegas-Pequignot E, Zafrani B, Malfoy B, Dutrillaux B: Recurrent homogeneously staining region in 8p1 in breast cancer and lack of amplification of POLB, LHRH, and PLAT genes. Cancer Genet Cytogenet 52:27–35, 1991.PubMedGoogle Scholar
  143. 143.
    Zafrani B, Gerbault-Sseureau M, Mosseri V, Dutrillaux B: Cytogenetic study of breast cancer: clinicopathologic significance of homogeneously staining regions in 84 patients. Hum Pathol 23:542–547, 1992.PubMedGoogle Scholar
  144. 144.
    Gebhart E, Bruderlein S, Augustus M, Siebert E, Feldner J, Schmidt W: Cytogenetic studies on human breast carcinomas. Breast Cancer Res Treat 8:125–138, 1986.PubMedGoogle Scholar
  145. 145.
    Muleris M, Almeida A, Gerbault-Seureau M, Malfoy B, Dutrillaux B: Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosom Cancer 10:160–170, 1994.PubMedGoogle Scholar
  146. 146.
    Almeida A, Muleris M, Dutrillaux B, Malfoy B: The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosom Cancer 11:63–65, 1994.PubMedGoogle Scholar
  147. 147.
    Bello MJ, Rey JA: Cytogenetic analysis of metastatic effusions from breast tumors. Neoplasma 36:71–81, 1989.PubMedGoogle Scholar
  148. 148.
    Saint-Ruf C, Gerbault-Seureau M, Viegas-Pequignot E, Zafrani B, Cassingena R, Dutrillaux B: Proto-oncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosom Cancer 2:18–26, 1990.PubMedGoogle Scholar
  149. 149.
    Trent JM, Weber B, Guan XY, Zhang J, Collins F, Abel K, Diamond A, Meltzer P: Microdissection and microcloning of chromosomal alterations in human breast cancer. Breast Cancer Res Treat 33:95–102, 1995.PubMedGoogle Scholar
  150. 150.
    Kallioniemi A, Kallioniemi O, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW, Waldman FM: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91:2156–2160, 1994.PubMedGoogle Scholar
  151. 151.
    Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo W, Waldman FM, Isola JJ, Gray JW, Kallioniemi O: Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 54: 4257–4260, 1994.PubMedGoogle Scholar
  152. 152.
    Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors. Cancer Res 52:1036–1039, 1992.PubMedGoogle Scholar
  153. 153.
    Klein G, Klein E: Evolution of tumors and the impact on molecular oncology. Nature 315:190–195, 1985.PubMedGoogle Scholar
  154. 154.
    Takita K, Sato T, Miyagi M, Watatani M, Akiyqmq F, Sakmoto G, Kasumi F, Abe R, Nakamura Y: Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res 52:3941–3917, 1992.Google Scholar
  155. 155.
    Holzlsouer KJ, Harris EL, Parshad R, Fogel S, Bigbee WL, Sanford KK: Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer 64:14–17, 1995.Google Scholar
  156. 156.
    Tsuda H, Hirohashi S: Identification of multiple breast cancers of multicentric origin by histological observations and distribution of allele loss on chromosome 16q. Cancer Res 55:3395–3398, 1995.PubMedGoogle Scholar
  157. 157.
    Magdelenat H, Gerbault-Seureau M, Laine-Bidron C, Prieur M, Dutrillaux B: Genetic evolution of breast cancer: II. Relationship with estrogen and progesterone receptor expression. Breast Cancer Res Treat 22:119–127, 1992.PubMedGoogle Scholar
  158. 158.
    Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:67–71, 1994.Google Scholar
  159. 159.
    Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265:2088–2090, 1994.PubMedGoogle Scholar
  160. 160.
    Li FP, Fraumni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362, 1988.PubMedGoogle Scholar
  161. 161.
    Weksberg R, Teshima I, Williams BRG, Greenberg CR, Pueschel SM, Chernos JE, Fowlow SB, Hoyme E, Anderson IJ, Whiteman DAH, Fisher N, Squire J: Molecular characterization of cytogenetic alterations associated with the Beckwith-Wiedemann syndrome (BWS) phenotype refines the localization and suggests the gene for BWS is imprinted. Human Mol Genet 2:549–556, 1993.Google Scholar
  162. 162.
    Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, Barrett-Lee P, Easton DF, Ponder BAJ: A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genet 2:132–134,1992.PubMedGoogle Scholar
  163. 163.
    Lobaccaro J, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, Heron J, Pujol H, Sultan C: Male breast cancer and the androgen receptor gene. Nature Genet 5:109–110, 1993.PubMedGoogle Scholar
  164. 164.
    Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, Osborne MP, Kinne DA, Rosen PP: Breast cancer in patients irradiated for Hodgkin’s disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10:1674–1681, 1992.PubMedGoogle Scholar
  165. 165.
    Hurlimann J, Larrinaga B, Vala DLM: bcl-2 protein in invasive ductal breast carcinomas. Virchows Archiv 426:163–168, 1995.PubMedGoogle Scholar
  166. 166.
    Colomer R, Lupu R, Bacus SS, Gelmann EP: erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70:819–825, 1994.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1997

Authors and Affiliations

  • Marilyn L. Slovak

There are no affiliations available

Personalised recommendations